+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
P

Actively Recruiting

Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.

Age: 18Years - 80YearsAll GendersPhase 3
345 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and patient-reported outcomes of a port delivery system PDS implant delivering ranibizumab for people with neovascular age-related macular degeneration nAMD. This study focuses on a 36-week refill schedule for the PDS implant filled with ranibizumab 100 mgmL. Participants include adults aged 50 and older with recent nAMD diagnosis and prior anti-VEGF treatment response. Participants will have the PDS implant surgically inserted in the study eye, containing approximately a 2-mg dose of ranibizumab. Based on disease activity at Week 24 or use of supplemental ranibizumab injections before Week 24, participants will receive implant refill exchanges every 24 weeks or every 36 weeks if disease activity criteria are not met. Supplemental intravitreal ranibizumab injections may be given as needed. During the study, participants will undergo regular assessments including visual acuity tests using the ETDRS chart and optical coherence tomography OCT imaging to monitor eye health and treatment effects. The study will track visual acuity changes, supplemental treatments, adverse events, and patient preferences over approximately 72 weeks. Safety and device-related events will be monitored up to around 19 months. The total participation duration aligns with the study completion date in 2028.

Age: 50Years +All GendersPhase 3
61 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness, feasibility, and safety of a bicycle exercise followed by an intensive lifestyle intervention over three months in patients recently diagnosed with and not yet treated for type 2 diabetes. The study focuses on early lifestyle changes as a first-line treatment to control metabolic problems without medication. This approach seeks to show the benefits of exercise and diet changes, especially in patients with symptoms like increased urination and thirst, who often receive immediate drug treatment instead. Participants are randomly assigned to either standard care or an intervention group that performs a 30-minute bicycle exercise at 60% of their maximum heart rate, followed by a lifestyle program including 3 to 5 aerobic sessions and 2 resistance trainings per week, plus weekly motivational coaching calls. The study involves a symbolic removal of the emergency room bed to encourage exercise immediately after diagnosis. Follow-up visits occur at 2, 7, 30, 60, and 90 days, as well as at 6 months and one year. During the study, participants will monitor blood glucose at home, sending fasting glucose readings to the research team for ongoing metabolic monitoring. Clinical measurements like heart rate, blood pressure, blood gases, and HbA1c will be taken at multiple time points. Activity levels will be tracked by mobile phone and an activity tracker. The main outcome is metabolic control without medication after 3 months, with additional evaluations of physical activity, safety, and quality of life over time.

Age: 18Years +All GendersPhase Not Applicable
3 locations
S

Actively Recruiting

Researchers are evaluating the effects of canakinumab compared to placebo in patients experiencing postprandial hypoglycemia after bariatric surgery. This condition can significantly reduce quality of life and currently has no approved drug treatments. The trial aims to determine if canakinumab can improve mental and physical health-related quality of life and reduce hypoglycemic episodes. Participants will receive either a single subcutaneous injection of 150 mg canakinumab or a placebo injection of saline solution. The study includes a 10-day screening phase using a blinded continuous glucose monitoring system to confirm hypoglycemia, followed by a 28-day treatment period with three study visits for monitoring and data collection. After treatment, participants will have a follow-up visit two months later to assess longer-term effects. During the study, participants will wear glucose monitors, keep diaries, and report any adverse events. Researchers will measure changes in quality of life, frequency of hypoglycemic events, hypoglycemia symptoms, fear of hypoglycemia, glucose patterns, body weight, and safety outcomes. The total participation time is up to four months, including screening, treatment, and follow-up assessments.

Age: 18Years - 75YearsAll GendersPhase 3
2 locations
C

Actively Recruiting

Researchers are investigating the best approach to treat low-risk patients with isolated subsegmental pulmonary embolism SSPE, a type of blood clot in small lung arteries. The study aims to determine whether monitoring patients without anticoagulation is as safe and effective as giving anticoagulant medication. This is important because many patients currently receive anticoagulants that carry a risk of bleeding, but it is unclear if all patients with isolated SSPE need this treatment. Patients in the trial are randomly assigned to one of two groups. One group receives the anticoagulant drug rivaroxaban, starting with 15 mg twice daily for 21 days, then 20 mg once daily for a total of 90 days. The other group receives a placebo matching the same schedule. The trial compares clinical surveillance without anticoagulation to anticoagulation treatment to assess safety and effectiveness. Participants will be followed for 90 days after randomization to monitor for recurrent venous thromboembolism, significant bleeding events, and overall survival. Researchers will track these outcomes through clinical assessments and safety monitoring. This study is designed to evaluate if careful monitoring alone is a safe alternative to anticoagulation in selected patients with isolated SSPE, potentially reducing bleeding risks from treatment.

Age: 18Years +All GendersPhase 4
40 locations
S

Actively Recruiting

Atrial fibrillation is the most common heart rhythm problem worldwide and increases the risk of heart failure, stroke, and death. Researchers expect its prevalence to rise, especially in people over 65 years old, with about one in three developing atrial fibrillation. Electrocardioversion is a procedure that restores normal heart rhythm but often results in the arrhythmia returning within a short time. This trial aims to study whether inflammation plays a role in this recurrence and if treating it can reduce the return of atrial fibrillation after electrocardioversion. The trial compares two groups one receives a daily oral dose of 0.5 mg Colchicine for three months, taken in the morning without a loading dose, alongside their usual treatments. The other group receives a matched placebo. This is a randomized, triple-blind Phase 3 study evaluating the effect of low-dose Colchicine on preventing atrial fibrillation recurrence after electrocardioversion. Participants will be monitored for recurrence of atrial fibrillation over six months following electrocardioversion. Researchers will assess the number of arrhythmia recurrences at one, three, and six months, the time to any repeat electrocardioversion, use of antiarrhythmic drugs, and hospitalizations. Safety and overall wellbeing will also be followed during this period, with the main outcome focused on arrhythmia recurrence within six months.

Age: 18Years +All GendersPhase 3
8 locations
S

Actively Recruiting

Researchers are evaluating dapansutrile, an oral NLRP3 inhibitor, as a potential new treatment option for managing type 2 diabetes and its related complications. This study focuses on whether dapansutrile, which has shown promising preclinical and safety results, can reduce inflammation and address risks for cardiovascular disease associated with diabetes. The trial is a phase 2, randomized, double-blind, placebo-controlled study over 26 weeks. Participants will be randomly assigned to receive either 1000 mg of dapansutrile twice daily or a matching placebo for 26 weeks. All tablets are self-administered orally with or without food. The study compares the effects of dapansutrile against placebo on blood sugar control and inflammation over the treatment period. Throughout the trial, participants will undergo regular blood tests to measure HbA1c and fasting plasma glucose levels at baseline and multiple time points up to week 26. Researchers will also assess markers of inflammation and monitor safety. The primary outcome is the change in HbA1c from baseline to week 26. Participants are expected to complete all study procedures over approximately six months, with ongoing safety and efficacy evaluations.

Age: 18Years - 75YearsAll GendersPhase 2
6 locations
S

Actively Recruiting

Researchers are investigating whether adding a new medicine called tirzepatide, a glucose-dependent insulinotropic polypeptide GIPglucagon-like peptide-1 receptor agonist GLP-1RA, to usual insulin therapy can improve blood sugar control in adults with type 1 diabetes T1D. The study is designed as a prospective, randomized clinical trial to evaluate this combinations effect on glucose management, aiming to provide new options beyond standard insulin treatment. About 30% of adults with T1D currently meet recommended blood sugar targets, highlighting the need for improved therapies. The study will enroll adults aged 18 to 65 years with T1D diagnosed for at least 12 months who are already using automated insulin delivery AID systems. Participants will be randomly assigned to either continue their standard care or to add once-weekly injections of tirzepatide, starting at a low dose of 2.5 mg and increasing to 5 mg weekly for 12 weeks. The trial includes a 4-week dose titration phase followed by 12 weeks of treatment, comparing glucose control outcomes between groups. Participants will wear a continuous glucose monitor CGM and share their glucose and insulin data throughout the 16-week study. Researchers will assess time spent within target glucose ranges, changes in blood sugar levels, insulin doses, and body weight. Safety and adherence will be monitored during the trial. The study aims to gather important data on whether tirzepatide can help improve glucose control and quality of life for adults living with T1D.

Age: 18Years - 65YearsAll GendersPhase 3
3 locations

1-10 of 23

1